AmSurg receives $90 price target — 5 notes

Cantor Fitzgerald rated AmSurg shares, according to The Cerbat Gem.

Advertisement

Here are five notes:

1. The firm gave AmSurg a $90 price target.

2. Cantor Fitzgerald has a “buy” rating on AmSurg shares.

3. The price target indicates a 43.75 percent potential upside for AmSurg shares.

4. The market cap. is $3.37 billion.

5. AmSurg’s P/E ratio is 18.58.

More articles on surgery centers:
Carle submits CON application to relocate surgery center — 5 takeaways
How physicians and hospitals can benefit from joint ventures
Independent vs. hospital-associated ASCs: Mutually assured destruction or an uneasy truce?

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.